AVEO Oncology announces immuno-oncology clinical collaboration with AstraZeneca
AVEO Oncology announced a collaboration with AstraZeneca to evaluate safety and efficacy of AstraZeneca's IMFINZI® (durvalumab) directed against PD-L1, in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent and highly-selective VEGFR-TKI in first-line HCC in a Phase 1/2 study. December 12, 2018